Ovine Corticotropin-Releasing Hormone (oCRH)

PreclinicalSmall molecule

EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Ovine Corticotropin-Releasing Hormone (oCRH) is one of 13 small molecule programs targeting Adrenal insufficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adrenal InsufficiencyActive, not recruiting

Adrenal InsufficiencyPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Adrenal Insufficiency

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

8 2

Rayos

RRoxane Laboratories

Approved

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Dehydroepiandrosterone

IInflabloc Pharmaceuticals

Phase 3

1 5

Fludrocortisone 0.1 Milligrams (mg)

GGanin Fertility Center

Approved

1 6

Mifeprex

DDanco

Phase 2

1 7

Infacort

NNeurocrine UK Limited

Phase 3

1 8

Megace

Bristol-Myers Squibb

Preclinical

—9

Plenadren

UUniversity of Roma La Sapienza

Phase 2

1 10

Chronocort

NNeurocrine UK Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adrenal insufficiency1 trial

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)··NCT00001180·2,250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ovine Corticotropin-Releasing Hormone (oCRH). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ovine Corticotropin-Releasing Hormone (oCRH) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ovine Corticotropin-Releasing Hormone (oCRH). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Ovine Corticotropin-Releasing Hormone (oCRH)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adrenal insufficiency1 trial

References

Drug Info

Quick Facts

Related News